Pharma major Lupin Limited won the gold award at the 9th Annual Conference on Quality Management, organised by the American Society for Quality at Ahmedabad on 22 November, 2019. The nomination case study submitted for this award summarised the transformation project to improve the yield and quality of Lupin’s Cefadroxil products.
Speaking on the occasion, Rajendra B Chunodkar, President – Manufacturing Operations, lupin ltd. said, “It is a moment of pride. This is the fourth consecutive year that Lupin’s Ankleshwar facility has won the Gold Award from the American Society for Quality. As a leading pharmaceutical company, we have constantly focused our efforts towards enabling manufacturing excellence at all our manufacturing sites. This award highlights and validates our approach toward quality and continuous improvement.”
While, this year Lupin’s nomination highlighted the key outcomes of its “Cefadroxil Yield and Quality Improvement” project, in the past three years, Lupin won the award for projects that focused on Ethambutol Yield Improvement (2018), 7AE Yield Improvement {2017) and 7ACCA Yield Improvement (2016).
Lupin is the 9th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVI/ MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.